Antipsychotic agents in the treatment of somatoform disorders; a review;Gebruik van antipsychotica bij somatoforme stoornissen; een literatuuroverzicht

Tijdschrift voor Psychiatrie

Volumn 53, Issue 3, 2011, Pages 163-173

  Decoutere, L ^a   Van Den Eede, F ^a   Moorkens, G ^a   Sabbe, B G C ^a  

^a NONE

Author keywords

Antipsychotic agents; Functional disorders; Somatoform disorders; Treatment

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; CISAPRIDE; DIAZEPAM; FLUOXETINE; FLUPENTIXOL; FLUSPIRILENE; MELITRACEN; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PIMOZIDE; QUETIAPINE; SERTRALINE; SULPIRIDE; ZIPRASIDONE;

ARTICLE; BODY DYSMORPHIC DISORDER; DRUG EFFICACY; DRUG INDICATION; DRUG TREATMENT FAILURE; DYSPEPSIA; FIBROMYALGIA; FUNCTIONAL DISEASE; GLOSSODYNIA; HUMAN; HYPOCHONDRIASIS; MEDICAL LITERATURE; MEDLINE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMATOFORM DISORDER; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; FLUPENTHIXOL; HUMANS; SOMATOFORM DISORDERS; SULPIRIDE; TREATMENT OUTCOME;

EID: 79952778037     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4de druk). Washington: APA; 1994.
2. Arienti V, Corazza GR, Sorge M, Boriani L, Ugenti F, Biagi F,e.a. The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia. Aliment Pharmacol Ther 1994;8:631-8.
3. Calandre EP, Hidalgo J, Rico-Villademoros F. Use of ziprasidone in patients with fibromyalgia: a case series. Rheumatol Int 2007; 27:473-6. (Pubitemid 46294988)
4. Distrutti E, Fiorucci S, Hauer K, Pensi O, Vanasia M, Morelli A. Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. Aliment Pharmacol Ther 2002;16:613-22. (Pubitemid 34214543)
5. Ferrerri M, Florent C, Gerard D. Sulpiride: étude chez 669 patients présentant un trouble douloureux d'origine psychologique. L'Encéphale 2000;16:58-66.
6. Freedenfeld RN, Murray M, Fuchs PN, Kiser RS. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. Pain Pract 2006;6:112-8. (Pubitemid 43676681)
7. Gick CL, Mitowski GW, Kennedy JS, Bymaster FP. Treatment of glossodynia with olanzapine. J Am Acad Dermatol 2004;51:463-5.
8. Grant J. Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report. J Clin Psychiatry 2001;62:297-8. (Pubitemid 32428773)
9. Hashash JG, Abdul-Baki H, Azar C, Elhajj II, El Zahabi L, Chaar HF, e.a. Clinical trial: a randomized controlled cross-over study of flupentixol + melitracen in functional dyspepsia. Aliment Pharmacol Ther 2008;27:1148-55.
10. Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet 2007;369:946-55.
11. Hidalgo J, Rico-Villademoros F, Calandre E. An open-label study of quetiapine in the treatment of fibromyalgia. Progress Neuropsychopharmacol Biol Psychiatry 2007;31:71-7. (Pubitemid 44959248)
12. Houdenhove B Van. Als je moet bewijzen dat je ziek bent... . Tijdschr Psychiatr 2005;47:369-70.
13. Joukamaa M, Sohlman B, Lehtinen V. The prescription of psychotropic drugs in primary health care. Acta Psychiatr Scand 1995; 92:359-64.
14. Kalis D, Ten Over GHM, Etdmann JF. Fluspitilene (Imap) in the treatment of psychosomatic complaints in hypochondriacal patients. Acta Psychiatr Belg 1980;80:321-8. (Pubitemid 11165994)
15. Kiser RS, Cohen HM, Freedenfeld RN, Jewell C, Fuchs PN. Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage 2001;22:704-8.
16. Kozian R. Olanzapine in therapy of a somatoform disorder. Psychiatr Praxis 2003;30:450-1.
17. Lanfranchi GA, Bazzochi G, Marzio L, Campieri M, Brignola C. Inhibition of postprandial colonic motility by sulpiride in patients with irritable colon. Eur J Clin Pharmacol 1983;24:769-72. (Pubitemid 13064468)
18. Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002;63:38-43. (Pubitemid 34113485)
19. Mansi C, Borro P, Giacomini M, Biagini R, Mele MR, Pandolfo N, e.a. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000;14:561-9.
20. Mayou R, Kirmayer L, Simon G, Kroenke K, Sharpe M. Somatoform disorders: time for a new approach in DSM-V. Am J Psychiatry 2005;162:847-55. (Pubitemid 40676195)
21. Mearin F, Rodrigo L, Petez-Mota A, Balboa A, Jiménez I, Sebastián JJ, e.a. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004;2:301-8.
22. Meyers C, Vranckx C, Eigen K. Psychosomatic disorders in general practice: comparisons of treatment with flupentixol, diazepam and sulpiride. Pharmatherapeutica 1985;4:244-50. (Pubitemid 15051624)
23. Mucci A, Nolfe G, Maj M. Levosulpiride: a review of its clinical use in psychiatry. Pharmacol Res 1995;31:95-101.
24. Nakaaki S, Murata Y, Furukawa T. Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder. Psychiatry Clin Neurosci 2008;62:370. (Pubitemid 351832321)
25. Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 2005a;162:1022-3. (Pubitemid 40676228)
26. Phillips KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 2005b;162:377-9. (Pubitemid 40216220)
27. Rico-Villademoros F, Hidalgo J, Dominguez I, García-Leiva JM, Calandre EP. Atypical antipychotics in the treatment of fibromyalgia: a case series with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:161-4.
28. Ring A, Dowrick C, Humpris G, Salmon P. Do patients with unexplained physical symptoms pressurise general practitioners for somatic treatment? A qualitative study. BMJ 2004;328:1057.
29. Rouillion F, Rahola G, Van Moffaett M, Lopes RG, Dunia I; Soma-D Study Team, e.a. Sulpiride in the treatment of somatoform disorders: results of a European observational study to characterize the responder profile. J Int Med Res 2001;29:304-13. (Pubitemid 32926986)
30. Trimbos-instituut in opdracht van de Landelijke stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ. Conceptrichtlijn Somatisch Onvoldoende verklaarde Lichamelijke Klachten en Somatoforme Stoornissen. Utrecht: Trimbos-instituut; 2009.
31. Ueda N, Kodama Y, Hori H, Umene W, Sugita A, Nakano H, e.a. Two cases of burning mouth syndrome treated with olanzapine. Psychiatry Clin Neurosci 2008;62:359-61.
32. Volz H, Stieglitz RD, Menges K, Möller HJ. Somatoform disorders - Diagnostic concept, Controlled clinical trials, and methodological issues. Pharmacopsychiatry 1994;27:231-7.
33. Waal MW de, Arnold IA, Eekhof J, van Hemert AM. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry 2004;184:470-6. (Pubitemid 38725705)
34. Zitman F, Linssen AC, Edelbroek P, van Kempen GM. Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitryptiline in somatoform pain disorder? Pain 1991; 47:25-30.